immediate sequential bilateral intravitreal injections: an indian perspective

Clicks: 234
ID: 245087
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #57 of 271 articles by views in e3s web of conferences

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 271 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Koushik Tripathy Department of Vitreoretina and Uvea, ICARE Eye Hospital and Postgraduate Institute, Sector-26, Noida, Uttar Pradesh, IndiaRecently, Ruão et al1 have shown in a study spanning 6 years that only 1 of 6560 (0.015%) eyes undergoing unilateral intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection developed culture-proven endophthalmitis. None of the 1612 eyes receiving immediate sequential bilateral intravitreal treatment (ISBIVT) with anti-VEGF injection developed endophthalmitis.1 Likewise, immediate sequential bilateral cataract surgery (ISBCS)2 has been proposed to provide “potentially decreased wait times for surgery, patient convenience and cost savings for health care payors”, with comparable visual outcomes and complication rates. However, in an Indian scenario, there is need for discussion regarding endophthalmitis following ISBIVT injections.View the original paper by Ruão and colleagues.
Reference Key
k2017clinicalimmediate Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Tripathy K
Journal e3s web of conferences
Year 2017
DOI
DOI not found
URL
https://www.dovepress.com/letter-safety-of-bilateral-same-day-intravitreal-injections-of-an-peer-reviewed-article-OPTH
Keywords
bevacizumab ranibizumab

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.